Immatics NV (IMTX)
10.88
+0.07
(+0.65%)
USD |
NASDAQ |
May 02, 16:00
10.88
0.00 (0.00%)
After-Hours: 19:31
Immatics Cash from Financing (TTM): 91.50M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 91.50M |
September 30, 2023 | 205.19M |
June 30, 2023 | 153.07M |
March 31, 2023 | 130.31M |
December 31, 2022 | 130.46M |
September 30, 2022 | 17.65M |
June 30, 2022 | 14.73M |
Date | Value |
---|---|
March 31, 2022 | -3.284M |
December 31, 2021 | -3.092M |
September 30, 2021 | -7.908M |
June 30, 2021 | 237.07M |
March 31, 2021 | 237.50M |
December 31, 2020 | 237.41M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-7.908M
Minimum
Sep 2021
237.50M
Maximum
Mar 2021
110.82M
Average
130.31M
Median
Mar 2023
Cash from Financing (TTM) Benchmarks
MorphoSys AG | -- |
Affimed NV | -6.734M |
InflaRx NV | 57.36M |
BioNTech SE | -842.92M |
CureVac NV | 249.97M |